Structure Therapeutics (NASDAQ:GPCR) Stock Rating Reaffirmed by Cantor Fitzgerald

Structure Therapeutics (NASDAQ:GPCR)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a note issued to investors on Monday, Benzinga reports. They presently have a $65.00 price objective on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 36.78% from the stock’s previous close.

Several other research firms have also weighed in on GPCR. BMO Capital Markets lifted their target price on shares of Structure Therapeutics from $83.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, June 7th. JMP Securities reissued a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a report on Friday, May 10th. Lifesci Capital reissued an “outperform” rating on shares of Structure Therapeutics in a report on Tuesday, February 27th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Structure Therapeutics in a report on Tuesday, May 21st. They issued an “overweight” rating and a $65.00 price target for the company. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics presently has an average rating of “Buy” and an average price target of $85.25.

Structure Therapeutics Trading Down 2.2 %

Shares of NASDAQ GPCR opened at $47.52 on Monday. The stock has a market cap of $2.22 billion and a price-to-earnings ratio of -61.71. The company has a 50 day simple moving average of $40.89 and a two-hundred day simple moving average of $42.52. Structure Therapeutics has a 12 month low of $25.57 and a 12 month high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, May 9th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.02. Analysts forecast that Structure Therapeutics will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

A number of large investors have recently modified their holdings of the business. Teachers Retirement System of The State of Kentucky boosted its position in shares of Structure Therapeutics by 17.8% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 13,733 shares of the company’s stock valued at $589,000 after acquiring an additional 2,077 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Structure Therapeutics during the 1st quarter valued at about $308,000. RA Capital Management L.P. boosted its position in shares of Structure Therapeutics by 210.2% during the 1st quarter. RA Capital Management L.P. now owns 1,510,362 shares of the company’s stock valued at $64,734,000 after acquiring an additional 1,023,530 shares during the last quarter. Artal Group S.A. boosted its position in shares of Structure Therapeutics by 75.3% during the 1st quarter. Artal Group S.A. now owns 151,780 shares of the company’s stock valued at $6,505,000 after acquiring an additional 65,180 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of Structure Therapeutics by 34.5% during the 1st quarter. Janus Henderson Group PLC now owns 2,076,700 shares of the company’s stock valued at $88,994,000 after acquiring an additional 532,284 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.